PURPOSE

The New England Science Symposium (NESS), established in 2002, promotes careers in biomedical sciences. NESS provides a forum for postdocs (research and clinical); medical, dental and graduate students; post-baccalaureates; college and community college students (particularly Black/African-American, Hispanic/LatinX and Native American/Alaska Native individuals) to share their biomedical and health-related research activities through oral or poster presentations, to engage in discussions related to career development in the sciences, to exchange ideas and to expand their professional networks.

NEW! Abstract Feedback Session - December 4, 2021. This session is designed for individuals who wish to receive feedback on their abstract from advisors and peers before submitting it. The meeting will be set-up in small groups (5-7 individuals) where students will give 2-4 minute elevator pitch to the group. Participating in this session is not required, nor does it guarantee acceptance.

If you are interested in, please prepare your abstract and submit your application by November 16th at the link below.
https://hms.az1.qualtrics.com/jfe/form/SV_9yOXoJ39YxWD4Wy (Please have your ABSTRACT ready BEFORE beginning the application.)

ABSTRACT SUBMISSION

Abstracts should be submitted by postdocs (research and clinical); medical, dental and graduate students; post-baccalaureates; college and community college students (particularly Black/African-American, Hispanic/LatinX and Native American/Alaska Native individuals) involved in biomedical or health-related scientific research.

The abstract must include:

1. Name of author(s)
2. Suffixes (if a degree is obtained): BS, MS, PharmD, MD, PhD, MD/PhD, DMD/DDS or other
3. Contact information: mailing and e-mail addresses, phone numbers
4. Institution, academic level and expected year of graduation/program completion
5. Funding source(s)/research sponsor(s)
6. Research title
7. The abstract (not to exceed 400 words) must demonstrate the scientific problem and must contain:
   • Statement of the Problem/Background
   • Research Question/Hypothesis
   • Research Design/Methods Used in the Investigation
   • Results/Summary of the Investigation
   • Interpretation/Conclusion of the Investigation

All abstracts will be reviewed and applicants notified of their acceptance by the end of February 2022.

Deadline for Abstract Submission: January 14, 2022
All abstracts must be submitted online at www.NewEnglandScienceSymposium.org
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Vertex discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

**Twenty-first Annual New England Science Symposium**

**Registration to Attend**

There is no registration fee, but pre-registration is required. Attendee registration will be available Spring 2022.

*For more information, please contact:*

Rodolfo Ramos, M.B.A., Program Manager
Office for Diversity Inclusion and Community Partnership | Harvard Medical School
Phone: 617.432.5580 | Rodolfo_Ramos@hms.harvard.edu

**AWARDS**

- **Ruth and William Silen, M.D. Awards**
  The Ruth and William Silen, M.D. Awards for outstanding oral presentations and exceptional scientific posters.

- **Dana-Farber/Harvard Cancer Center Awards**
  The Dana-Farber/Harvard Cancer Center Awards for outstanding cancer-related oral and poster presentations.

- **Postdoctoral Awards**
  Postdoctoral Awards for outstanding scientific posters presented by postdoctoral participants. Sponsored by Vertex.

- **American Cancer Society Awards**
  The American Cancer Society Awards for outstanding cancer-related oral and poster presentations.

- **Beth Israel Deaconess Medical Center Department of Neonatology Award**
  The Beth Israel Deaconess Medical Center Department of Neonatology Award for outstanding neonatal-perinatal research poster presentation.

- **Stem Cell and Regenerative Medicine Award**
  The Stem Cell and Regenerative Medicine Award for outstanding stem cell and regenerative medicine poster presentation.

- **Prophet Genomics Translational Research Award**
  Prophet Genomics Award recognizes one outstanding translational research poster presentation.

**SPONSORS**

- **Harvard Medical School Minority Faculty Development Program (MFDLP)**
  The Minority Faculty Development Program (est. 1990) of the Office for Diversity Inclusion and Community Partnership (est. 2002; originally named Faculty Development and Diversity) sponsors programs for the development of Harvard Medical School faculty and trainees, with an emphasis on mentoring and leadership. In addition, MFDLP addresses issues of increasing the pool of minority and disadvantaged students interested in careers in science and medicine, and has built a three-pronged effort to encourage minority and disadvantaged students from all levels of the educational pipeline to pursue biomedical, STEM and health-related careers. Programs begin as early as the middle school level and carry on through the postgraduate level and involve curriculum development, teacher training, enhancing student research, and career development.

- **Biomedical Science Careers Program (BSCP)**
  BSCP was founded in 1991 by MFDLP in collaboration with the Massachusetts Medical Society and the New England Board of Higher Education to identify, inform, support and provide mentoring for academically outstanding minority students and fellows ranging from high school to postdoctoral level.

**SUPPORTER**

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Vertex discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.